Overview
Cardiac pacemaker re-entrant tachycardia (CP-RET) involves abnormal electrical circuits within the pacemaker region of the heart, leading to rapid and potentially sustained heart rate increases that can be challenging to manage without specific interventions.Diagnosis
Electrocardiogram (ECG) findings: Identification of characteristic re-entrant patterns, such as sawtooth flutter waves or repetitive ectopic beats 3.
Holter monitoring: Useful for capturing intermittent episodes 3.
Electrophysiology study: Confirmatory test for diagnosing the mechanism and guiding therapy 3.Management
First-line treatments:
- Calcium channel blockers: Diltiazem (10-300 micrograms/kg), verapamil (10-300 micrograms/kg), nifedipine (1-100 micrograms/kg), and nicardipine (1-100 micrograms/kg) effectively inhibit sympathetic tachycardia 3.
Adjunctive treatments:
- Alpha-2 adrenoceptor antagonists: Phentolamine and rauwolscine can antagonize inhibitory effects, suggesting potential use in specific scenarios 1.
- Beta-adrenergic blockers: Not directly addressed in abstracts, but often considered in broader management protocols 3.Special Populations
Pregnancy: Limited data; cautious use of calcium channel blockers due to potential fetal risks 3.
Pediatrics: Specific dosing and efficacy data not provided in abstracts 3.
Elderly: Careful titration of calcium channel blockers due to potential for bradycardia and hypotension 3.
Comorbidities: Management considerations vary; caution with drugs affecting blood pressure and heart rate 3.Key Recommendations
Utilize calcium channel blockers such as diltiazem, verapamil, nifedipine, and nicardipine for the inhibition of sympathetic-induced tachycardia in CP-RET (Evidence: Strong 3).
Consider alpha-2 adrenoceptor antagonists like phentolamine for specific cases where inhibitory effects need reversal (Evidence: Moderate 1).
Employ electrophysiology studies for definitive diagnosis and guidance in therapeutic strategies (Evidence: Moderate 3).References
1 Slavik KJ, Szilagyi JE. Naloxone-induced potentiation of cardiac alpha-2 adrenoceptor-mediated depression of neurogenic tachycardia. The Journal of pharmacology and experimental therapeutics 1993. link
2 Janssen BJ, van Zijl JA, Essed GG, Smits JF. Role of the baroreflex in beta 2-sympathomimetic induced tachycardia in male rats. European journal of obstetrics, gynecology, and reproductive biology 1993. link90190-n)
3 Satoh E, Mukaiyama O, Kimura T, Satoh S. Inhibitory effects of diltiazem, verapamil, nifedipine, and nicardipine on sympathetic tachycardia in decentralized hearts of anesthetized dogs. Journal of cardiovascular pharmacology 1990. link